G.d. Searle & Company

Abbott Laboratories Corporation

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Other

Aventis Pharma Limited

Rhone-poulenc Rorer Pharmaceuticals Inc.

Rhone Poulenc Rorer

C. D. Searle & Co.

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Makoto, Aoyama

Stevan Wakefield Djuric

Richard A Haack

Julie M Miyashiro

Thomas Dale Penning

Stella S Yu

Irini Akritopoulou-Zanze

Alan Frank Gasiecki

Stephen Hermann Docter

Wilfried Martin Braje

Ana-Lucia Relo

Hing L Sham

Anil Vasudevan

Zhonghua Pei

Frauke Pohlki

Paul E Wiedeman

Ying Wang

Jason T Brewer

Sean Colm Turner

Kent D Stewart

Kenton L Longenecker

Hong Yong

Chi-Dean Liang

Hongyu H Zhao

Michael John Clare

Zhenkun Ma

Barbara B Chen

Nizal S Chandrakumar

Jyoti R Patel

Bipinchandra N Desai

Qi Shuai

Xiaofeng Li

Kathy A Sarris

David J Madar

Bruce G Szczepankiewicz

Noel S Wilson

Daisy Pireh

John R Regan

Mark Andrew Russell

Keith W Woods

Daniel Gerard McGarry

Shashank Shekhar

Gregory Bernard Poli

Justin D Dietrich

David John Aldous

Paul Joseph Cox

Min Zhang

Dennie S Welch

Albert Wayne Kruger

Charles W Hutchins

Wilhelm Amberg

Udo Lange

Helmut Mack

Masateru Miyano

Richard F Clark

Michael Michaelides

Robert B Garland

Adrian Hobson

Marina Pliushchev

Nicole Teusch

Yanbin Lao

Douglas M Kalvin

Biqin C Li

Leland J Chinn

Lu Wang

Dawn M George

Brian D Wakefield

Henry Q Zhang

Peter Charles Astles

Anna M Ericsson

Christopher J Burns

Le Wang

Ly Tam Phan

Kerry W Fowler

Zhi-Fu Tao

Nan-Horng Lin

Joseph M Salvino

Gerard M Sullivan

Lee Daniel Arnold

Arthur Gomtsyan

Jerome F Daanen

Anthony C Scotese

Thomas J Sowin

Kristine E Frank

Kent W Neuenschwander

Vincent L Giranda

Alan S Florjancic

Richard W Dixon

Robert G Schmidt

Paul Rafferty

Laura A Hexamer

Michael M Friedman

Yunsong Tong

James H Holms

Robert D Groneberg

Zhiqin Ji

Robert L Shone

Douglas H Steinman

Eric C Breinlinger

Augustine Osuma

Carol K Wada

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R, R, R, R, R, R, X, X, X, X, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R, R, Rand m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

5-substituted indazoles as kinase inhibitors

The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV)

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2 -a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7 -octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2 -a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R, R, R, R, R, R, X, X, X, X, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

Compounds of formula (I) where X, C, and Dare defined herein, are inhibitors of polo-like kinases. The compounds of formula (I) are useful for treatment of diseases of cellular proliferation, such as, for example, cancer.

Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases

Growing community of inventors

Libertyville, IL, United States of America

Stevan Wakefield Djuric